BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Prism Pharmaceuticals, Inc. Raises $68 Million To Advance Acute Care Portfolio


9/18/2006 1:31:36 PM

KING OF PRUSSIA, Pa., Sept. 18 /PRNewswire/ -- Prism Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products, has secured up to $68 million in capital from Paul Capital Partners' Paul Royalty Fund II, L.P. ("Paul Capital") and existing investor Essex Woodlands Health Ventures Fund VI ("Essex").

Proceeds of $23 million were received upon the closing of this transaction, through the sale of preferred stock to both Paul Capital and Essex. Additional amounts of up to $45 million, comprised of both equity and a revenue interest financing, will be funded based on the satisfaction of certain predetermined milestones.

Concurrent with the financing, Prism also announced that Todd Davis and Clarke Futch of Paul Capital have joined the Prism board of directors, which also include James Currie and Petri Vainio of Essex and Warren Cooper, Prism's CEO.

"In order to accomplish our goal of becoming a leading specialty pharmaceutical company in the acute care space, we needed the support and funding from the investment community," said Warren Cooper, President and CEO of Prism. "We are pleased that Paul Capital has recognized our vision and understands our growth opportunities as we move closer to establishing a robust portfolio through the licensing of products and compounds in various stages of development. This funding allows us to move more rapidly towards creating unique and valid development pathways shaped by medical need and market opportunity."

"We believe Prism's product portfolio shows tremendous promise and we are confident in the ability of the company's strong management team to further develop and commercialize these products," said Todd Davis, Partner, Paul Capital Partners. "This transaction epitomizes the types of financing agreements we structure for growing companies in need of capital to fund their development and commercialization programs."

About Prism Pharmaceuticals, Inc.

Prism, founded in September 2004 and based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. For further information, visit http://www.prismpharma.com.

About Essex Woodlands Health Ventures

Essex Woodlands Health Ventures is one of the United States' premiere venture capital firms focusing exclusively on the healthcare industry. Essex Woodlands recently raised their seventh fund of $600 million. The firm has offices in California, Texas, New York and London. The Essex Woodlands team has been involved in the founding, investing, and/or management of over 100 healthcare companies ranging across all sectors, stages and geography. For more information, visit http://www.ewhv.com.

About Paul Capital Partners and Paul Royalty Fund

Paul Capital Partners manages nearly $5 billion in equity capital commitments for its three investment platforms that include Healthcare Royalty and Revenue Interests, Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London and Toronto. The Paul Royalty Fund is one of the largest dedicated healthcare funds globally, with approximately $1 billion in equity capital commitments. The Paul Royalty Fund has made investments in the pharmaceutical, biotechnology, and medical device sectors valued at more than $850 million. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests and equity. For more information, visit http://www.paulcapital.com.

Source: Prism Pharmaceuticals, Inc

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES